Introduction: The pharmacological profile of eprosartan - Implications for cerebrovascular and cardiovascular risk reduction

Current Medical Research and Opinion, Supplement

Volumn 23, Issue 5, 2007, Pages

  De La Sierra, Alejandro ^a   Ram, C Venkata S ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Angiotensin II type 1 receptor (AT1); Angiotensin II type 1 receptor blocker (ARB); Blood pressure; Cardiovascular risk; Cerebrovascular risk; Eprosartan; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPROSARTAN; HYDROCHLOROTHIAZIDE; LOSARTAN; NITRENDIPINE;

ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; COUGHING; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; HYPERTENSION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; STROKE;

ACRYLATES; AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; HUMANS; HYPERTENSION; IMIDAZOLES; MIDDLE AGED; RISK; THIOPHENES;

EID: 37849024866     PISSN: 01419951     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X260692     Document Type: Conference Paper

References (20)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
2. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
3. Rupp H, Jäger B. The rennin-angiotensin system and the sympathetic nervous system in hypertension and congestive heart failure: implications for therapeutic interventions. J Clin Basic Cardiol 2001;4:47-51
4. Givertz MM. Manipulation of the renin-angiotensin system. Circulation 2001;104:E14-18
5. Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977;57:313-70
6. Schmidt B, Drexler H, Schieffer B. Therapeutic effects of angiotensin (AT1) receptor antagonists: potential contribution of mechanisms other than AT1 receptor blockade. Am J Cardiovasc Drugs 2004;4:361-8
7. Verma S, Strauss M. Angiotensin receptor blocker and myocardial infarction. BMJ 2004;329:1248-9
8. Ram CVS. Angiotensin blockage with eprosartan: vascular and functional implications. Curr Med Res Opin 2007;23(Suppl. 5):S5-S11
9. Robins GW, Scott LJ. Eprosartan: a review of its use in the management of hypertension. Drugs 2005;65:2355-77
10. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
11. Bohm M, Sachse A. Safety and tolerability of eprosartan in combination with hydrochlorothiazide. Drug Saf 2002;25:599-611
12. Schrader J, Luders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-26
13. Rupp H. Risk reduction by preventing stroke: need for lockage of angiotensin II and catecholamines? Curr Med Res Opin 2007;23(Suppl. 5):S25-S29
14. Balt JC, Mathy MJ, Pfaffendorf M, et al. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. J Hypertens 2001;19:2241-50
15. Guimaraes S, Carneiro C, Brandao F, et al. A pharmacological differentiation between postjunctional (AT1A) and prejunctional (AT1B) angiotensin II receptors in the rabbit aorta. Naunyn Schmiedebergs Arch Pharmacol 2004;370:262-9
16. Ohlstein EH, Brooks DP, Feuerstein GZ, et al. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997;55:244-51
17. Arosio E, De MS, Prior M, et al. Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress. J Hypertens 2005;23: 1923-7
18. Neumann J, Ligtenberg G, Oey L, et al. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol 2004;15:2902-7
19. Shlyakhto E. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from >10,000 patients and review of literature. Curr Med Res Opin 2007;23(Suppl. 5): S13-S18
20. De Backer G. The SCORE model in the POWER study: an attempt to focus the limited resources for prevention on patients with greatest need. Curr Med Res Opin 2007;23 (Suppl. 5):S19-S24